Novel phenotype in beagle dogs characterized by skin response to compound 48/80 focusing on skin mast cell degranulation

Mitsuhiko UCHIDA1, 2), Fumi ITO1), Toshiyuki TSUCHIYA1), Yoko SHOJI1), and Toru KUROSAWA1)

1) Toxicology Laboratory, Pharmaceutical Research Center, Meiji Seika Pharma Co., Ltd., Kanagawa, Japan
2) Laboratory of Veterinary Pharmacology, School of Life and Environmental Sciences, Osaka Prefecture University, Osaka, Japan

Abstract: Beagle dogs have long been employed in toxicology studies and as skin disease models. Compared with other experimental animal species, they are known to be susceptible to skin responses, such as rashes, from exposure to various chemical compounds. Here, a unique dog phenotype was identified that showed no skin response to compound 48/80, a mast cell degranulating agent. Although the skin responses to intradermal injection of polyoxyethylene castor oil derivative (HCO-60, a nonionic detergent), histamine dihydrochloride, concanavalin A (IgE receptor-mediated stimuli), or calcium ionophore A23187 were comparable in wild-type (WT) dogs and these nonresponder (NR) dogs, only the response to compound 48/80 was entirely absent from NR dogs. The skin mast cell density and histamine content per mast cell were histologically comparable between WT and NR dogs. By checking for skin responses to compound 48/80, NR dogs were found to exist at the proportion of 17–20% among four animal breeders. From retrospective analysis of in-house breeding histories, the NR phenotype appears to conform to the Mendelian pattern of recessive inheritance. The standard skin response in WT dogs developed at 2–4 months of age. In conclusion, this unique phenotype, typified by insensitivity in the compound 48/80-induced degranulation pathway in mast cells, has been widely retained by recessive inheritance in beagle dogs among general experimental animal breeders. The knowledge concerning this phenotype could lead to better utilization of dogs in studies and aid in model development.

Key words: immunotoxicity, phenotype, rash, skin reaction
range of chemicals than other species, such as mice, rats, guinea pigs, and monkeys [5, 7, 9]. Indeed, in our laboratory, several drug candidates comprising small molecules have shown anaphylactoid reactions only in dogs, and dogs are sometimes not chosen as an experimental animal because of their hypersensitivity in studies of skin, gastrointestinal, and respiratory systems. It is thus important to investigate the characteristics of these dogs in view of the species utility in DISR assessment.

Investigations of anaphylactoid reactions have focused on the peptidergic pathway of mast cell activation, in addition to the other allergic pathway through the cross-linking of IgE bound to FcεRI receptors. The pathway to anaphylactoid reactions is activated by cationic secretagogues, including positively charged neuropeptides (e.g., substance P and neuropeptide Y), amines (e.g., compound 48/80 and natural polyamines), or cationic complement factors through nonspecific trimeric GTP-binding proteins (G_i proteins) via a receptor-independent but membrane-assisted process [10]. Inositol phospholipid breakdown by phosphatidylinositol 3-kinase or phospholipase C leads to intracellular Ca^{2+} elevation and subsequent mast cell degranulation [3]. This process is known to play an important role in neurogenic inflammation, tissue injury by venom peptides or pharmaceuticals, and diseases involving extensive activation of the blood complement cascade.

Beagle dogs have also been widely used for nonclinical toxicology studies, and in the course of long-term use, historical data have been accumulated and standardized at each dog-breeding facility. However, characteristics of these dogs, such as body weight, size, aggression, nervousness, and adaptability, have been seen to vary according to breeder, with large individual differences in susceptibility to test compounds observed even among littermates. The number of animals per test group in dog studies is usually less than the number in rodent studies, and thus, it is sometimes difficult in practice to evaluate test results due to these variations and small study sizes. Revealing the phenotype and its characteristics in beagle dogs is important from the perspective of understanding the range of variation and its effects on studies.

In this study, a novel subpopulation of nonresponder (NR) dogs, produced by selective breeding, was identified and investigated regarding their special phenotypic characteristics by morphological and pharmacological approaches using several stimulants of mast cell degranulation pathways. We also proposed a method for distinguishing wild-type (WT) and NR dogs through skin evaluation.

### Materials and Methods

#### Chemicals

Compound 48/80 was purchased from Sigma-Aldrich Corporation (St. Louis, MO, USA), HCO-60 was purchased from Nihon Surfactant Kogyo K.K. (Tokyo, Japan), histamine dihydrochloride was purchased from Nacalai Tesque, Inc. (Kyoto, Japan), Concanavalin A was purchased from Seikagaku Corp. (Tokyo, Japan), and A23187 was purchased from Alomone Labs, Ltd. (Jerusalem, Israel).

#### Animals

Beagle dogs of both sexes weighing approximately 8.5–12.5 kg were purchased from Covance Inc. (Cumberland, VA, USA), Marshall BioResources (North Rose, NY, USA), Ridglan Farms, Inc. (Mt. Horeb, WI, USA), and Nare Corp. (Narita, Japan); some of the Covance dogs were bred in-house. As for the beagle strains, HRA beagles from Covance and Nosan beagles from Nare were used. In totally 220 adult dogs and 88 pups were employed. Adult animals were housed individually in cages in an air conditioned facility with a temperature of 23 ± 2°C, relative humidity of 55 ± 10%, and light cycle of 7:00–19:00 and given standard chow (Labo D Stock, Nosan Corporation, Yokohama, Japan) at approximately 250 g/day and tap water ad libitum; the animal rooms and cages were cleaned daily. Skin diseases, such as atopic or infective dermatitis, were properly controlled and had not occurred before this study.

Dogs were used for experiments after a habituation period of more than 2 wk. All experimental protocols were approved by the Meiji Seika Pharma Institutional Ethics Committee for Use of Laboratory Animals in accordance with the principles outlined in the Guide for the Care and Use of Laboratory Animals prepared by Japanese Association for Laboratory Animal Science.

#### Vascular permeability to intradermal (ID)-injected compounds

Compound 48/80, HCO-60, histamine dihydrochloride, concanavalin A, or A23187 was dissolved in saline at 0.01–100 μg/ml and applied by ID injection at 0.05 ml/site into shaved thoracic skin under anesthesia with
25 mg/kg of pentobarbital. Just prior to ID injections, Evans blue (Tokyo Chemical Industry Co., Ltd., Tokyo, Japan) dissolved in saline was injected IV at 1 mg/kg. Approximately 10 min after IV injection, skin biopsies of injection sites were collected for pigment leakage determination, in which each skin sample was placed into a 1 N NaOH solution and incubated at 37°C overnight for pigment release. The optical density at 620 nm was measured for determination of pigment concentration per skin segment.

**Determination of skin mast cells and the degranulation ratio**

Skin mast cells and the histamine contained in them were visualized by toluidine blue staining and immunohistochemistry, respectively [5]. Dogs were anesthetized by intramuscular injection of 2 mg/kg xylazine hydrochloride followed by IV injection of 25 mg/kg sodium pentobarbital, and their lateral thorax was shaved. At 10–15 min after ID injection at 0.05 ml/site of either 10 µg/ml of compound 48/80 in saline or saline alone, punch biopsies were performed at the injection sites. Skin samples were treated sequentially for 2 h in Carnoy’s fixative and then for 1–2 h in 100% ethanol, and they were then embedded in paraffin and sectioned for subsequent histology. Mast cells were counted by microscope (×200) in 10 fields of toluidine blue (pH 0.5)-stained sections, and the ratio of degranulated to total mast cells was calculated. Degranulated mast cells were defined and judged by a fuzzy cell membrane and blue-stained granules scattered around the cells (Fig. 1A). The microscopic image/shape of mast cells did not differ between WT and NR dogs.

Immunohistochemistry for histamine was performed using skin samples from WT and NR dogs according to the manufacturer’s instructions for applying rabbit anti-histamine polyclonal antibody (#AB5885, Millipore Corporation, Billerica, MA, USA). Briefly, skin samples were fixed sequentially in 4% 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide and 4% paraformaldehyde (by vol) in a 250 W microwave for 20 min each and then immersed in 80% ethanol for 1 wk. Fixed samples were then embedded in paraffin and sectioned at a thickness of 4 µm. The sections were incubated in normal swine sera for blocking and sequential staining with primary antibody (#AB5885) at room temperature (r.t.) for 1 h and biotinylated anti-rabbit IgG at r.t. for 30 min, and they were then visualized using avidin-biotinylated horseradish peroxidase complex and 3,3′-diaminobenzidine tetrahydrochloride (DAB) substrate from a DAKO detection kit (Dako North America, Inc., Carpinteria, CA, USA) with washing steps using phosphate-buffered saline.

**Determination of NR dogs**

Gross skin responses in dogs were observed 10 min after ID or IV injection of compound 48/80. ID injection involved 0.01 mg of test chemical/ml saline and 0.05 ml/site, and IV injection involved 0.1 mg of test chemical/ml saline and 0.1 ml/kg body wt. Saline served as the negative control, and ID injections were made into shaved ventral neck skin. Dogs not showing any typical skin reactions from compound 48/80 applications were designated as NR dogs.

![Fig. 1. Representative photos of degranulated (A) or intact (B) skin mast cells from wild-type (WT) dogs IV treated with compound 48/80 at 1 mg/kg.](image-url)
Acute response to compound 48/80 in WT and NR dogs

Compound 48/80 dissolved in saline was administered at 0.1 ml/kg to 3 WT dogs and 3 NR dogs by intravenous (IV) bolus injection. The animals used here were originally purchased from Covance, Inc. and bred in-house. Skin and systemic responses were observed for 1 h after injection, and if the initial dog injected showed a marked response, the remaining 2 dogs were not treated. Injections to the same dogs were administered sequentially at intervals of at least one week.

Retrospective analysis of breeding histories

Breeding histories were retrospectively traced using available records and summarized. A working hypothesis was formulated in which the desired characteristics were transmitted in a recessive manner. The dominant/recessive gene of a dog was determined via analysis of skin test results from intradermal injection of compound 48/80 at 0.01 mg/ml.

Data analysis

Quantitative data are expressed as the mean ± standard error of the mean (SEM). Variance analysis between WT and NR dogs was conducted by F-test, and then the significance of the differences in Evans blue leakage between WT and NR dogs was estimated by Student’s t-test.

Results

Acute systemic and skin response to compound 48/80

When WT and NR dogs were IV injected with compound 48/80, WT dogs injected at 0.05–0.5 mg/kg showed typical skin and behavioral responses that were dose dependent, such as flares and swelling in abdominal skin and the face, mainly in the ear, eyelid, and corner of the mouth, and systemic signs that presented as scratching by the hind limbs, head shaking, and convulsions (Table 1). These responses were clearly seen 5–10 min after injection and disappeared within 30 min. In contrast, NR dogs did not show any skin response to compound 48/80, even at 1.5 mg/kg, but systemic responses were observed in NR dogs at 1.5 mg/kg. The systemic response might be induced by the off-target toxicity of compound 48/80.

Vascular permeability to stimulants of mast cell degranulation

Compound 48/80, HCO-60 (a surfactant), histamine dihydrochloride, concanavalin A (a chemical stimulant to IgE FcεR), and A23187 (a calcium ionophore) were ID administered to WT and NR dogs, and vascular permeability at the injection site was determined by pigment leakage. Of these chemicals, compound 48/80 showed poor dose-dependent pigment leakage in NR dogs (Fig. 2).

Morphological analysis for skin mast cells in NR dogs

Histological determination of mast cell numbers in normal skin showed that the density and numbers of mast cells were comparable between WT and NR dogs (123 ± 11 vs. 105 ± 10, respectively, Figs. 3A–C). In skin treated with compound 48/80 at 10 µg/ml, almost all mast cells in WT dogs were degranulated, while those in NR dogs were degranulated to a lesser extent (Fig. 3D). Also, the histamine content per mast cell in NR dogs was visually comparable to that in WT dogs (Fig. 4).

Proportion of NR dogs

Beagle dogs were purchased for experimental use from four commercial breeders, and the proportion of NR dogs was determined by skin response to ID or IV injection of compound 48/80. The proportion of NR dogs in each population was about 17–20% among the four breeder sources (Tables 2 A–D).

Table 1. Acute response to intravenous bolus injection of compound 48/80 in dogs

| Dose (mg/kg) | WT Phenotype | NR Phenotype |
|-------------|--------------|--------------|
| 0.05        | No remarks   | No data      |
| 0.15        | Flare (ear), swelling (face), urination, lacrimation | No remarks |
| 0.5         | Flare (ear), swelling (face), urination, lacrimation, prone position, convulsion | No remarks |
| 1.5         | No data      | Convulsion, limping, no skin response |

WT: wild-type. NR: nonresponder. n=1–3.
Breeding history

The in-house breeding history is retrospectively summarized in Table 3, using “A” and “a” to indicate the dominant and recessive gene, respectively, and “Aa” and “AA” to indicate wt and “aa” for Nr dogs. The proportions of wt and NR phenotype dogs were 65.0 and 35.0%, respectively, from heterozygous × heterozygous mating. All pups born by mating NR (homozygous recessive) dogs were determined to be NR dogs.

Age dependency of skin response in pups

Pups from three litters born from mating heterozygous Aa with homozygous recessive aa dogs were determined to be WT offspring by monthly testing of their skin response to ID or IV injection of compound 48/80. None of the pups at 1 month of age showed any response to ID injection of compound 48/80, and typical skin responses appeared at around 2–4 months of age in both sexes (Table 4). In clear contrast, NR dogs from the same litters did not show any skin response at any age (data not shown).

Discussion

A unique beagle phenotype was identified that showed no skin response to ID or IV injection of compound 48/80. The target pathway that defined the characteristics of the NR dogs studied here was concluded to be the Gi protein-mediated pathway to mast cell degranulation (Fig. 5). Mast cell reactivity to compound 48/80, not to other stimulants, was completely different between WT and NR dogs despite comparable populations and histo-

![Graphs showing vascular permeability to various compounds.](image)
Fig. 3. Determination of mast cells in dog skin. Representative photos of punched skin sections stained with toluidine blue from wild-type (WT) (A) and nonresponder (NR) (B) dogs (n=3); (C) mast cell density (cells/field, mean ± SEM) calculated by cell count in 10 fields (200×); (D) proportion of degranulated skin mast cells after treatment with compound 48/80 at 10 µg/ml; compound 48/80 at 10 µg/ml ID injected into lateral thorax skin under anesthesia; injection sites biopsied 10 min after injection; and calculated proportion (%, mean ± SEM) of degranulated mast cells to total mast cells.

Fig. 4. Representative photos of immunohistochemical analysis for histamine targeting in skin mast cells from wild-type (WT) (A) and nonresponder (NR) (B) dogs. Arrow heads, mast cells; histamine, dark brown.
NONRESPONDERS TO COMPOUND 48/80 IN DOGS

Table 2. Numbers of dogs tested and proportions of NR dogs from four breeders

| Breeder | A  | B  | C  | D  |
|---------|----|----|----|----|
| Total (n) | 22 | 113 | 46 | 29 |
| WT (n)  | 18 | 93 | 13 | 24 |
| NR (n)  | 4  | 20 | 9  | 5  |
| NR (%)  | 18% | 18% | 20% | 17% |

Table 3. Retrospective analysis of the breeding histories of the WT and NR dogs

| Cross | WT (AA/AA) | NR (aa) |
|-------|------------|---------|
|       | Male | Female | Total no. (%) | Male | Female | Total no. (%) |
| Hetero × Homo (Aa × aa) | 12  | 8    | 20 (43.5) | 14  | 12   | 26 (56.5) |
| Hetero × Hetero (Aa × Aa) | 6   | 7    | 13 (65.0)  | 4   | 3    | 7 (35.0)   |
| Homo × Homo (aa × aa)    | 0   | 0    | 0 (0)       | 15  | 7    | 22 (100)  |

Table 4. Skin or systemic responses to compound 48/80 in pups up to 5 months of age

| Pup No. | Sex | 1 mo, ID | 2 mo, ID | 3 mo, ID | 4 mo, IV | 5 mo, IV |
|---------|-----|----------|----------|----------|----------|----------|
| A1      | M   | –        | –        | –        | +        | +        |
| A2      | M   | –        | –        | +        | +        | +        |
| A3      | F   | –        | –        | +        | +        | +        |
| B1      | M   | –        | –        | +        | +        | +        |
| B2      | M   | –        | +        | +        | +        | +        |
| B3      | F   | –        | +        | +        | +        | +        |
| C1      | M   | –        | –        | +        | +        | +        |
| C2      | F   | –        | –        | +        | +        | +        |

Table 4. Skin or systemic responses to compound 48/80 in pups up to 5 months of age

WT: wild-type. NR: nonresponder.

Table 4. Skin or systemic responses to compound 48/80 in pups up to 5 months of age

ID, Intradermal injection; IV, Intravenous injection; -, no skin or systemic response; +, positive skin response described in Table 1. Pup No.: pups indicated by same letters are littermates.

Immune mediated

Non immune mediated

Concanavalin A

IGE

FceRI

PLCγ

Mast cell

A23187

Ca²⁺

Degranulation

Histamine and chemical mediators

Compound 48/80

GPCR

α

β

γ

Dysfunctional route in NR dogs

HCO-60

Skin response

Substance P, etc.

Fig. 5. Illustration of main pathways to skin response via mast cells based on results shown in Fig. 4. Nonresponder dogs showed skin responses to HCO-60, histamine dihydrochloride, concanavalin A, and A23187 comparable to those of wild-type dogs but no response to compound 48/80; the dysfunctional route in NR dogs would be downstream of the GPCR.
tion [4]. Although the interactions with G protein and specific receptors are unclear, compared with the mode of action of degranulation stimulators, the gene target that defines the characteristics observed in NR dogs would be a G protein-related molecule. A canine GeneChip® analysis performed using skin from WT and NR dogs did not detect strongly or weakly expressed pro/anti-inflammatory genes in either group (data not shown). The gene responsible for skin refractoriness in NR dogs has not yet been identified.

The presence of NR dogs was confirmed in the beagle populations from several general animal breeders (Table 2). In a few papers, a similar phenotype has been reported. One out of eight dogs was determined as NR, showing no histamine elevation in plasma or skin response to fluoroquinolones, which are known to induce anaphylactoid reactions [6]. Of 82 suspected atopic dogs, three showed poor skin responses to compound 48/80 injection, which would allow appropriate determination of their drug-induced skin responses. Also, application of this approach, for understanding individual characteristics, might lead to smaller study groups and a reduction of animal usage numbers.

The typical anaphylactoid skin response to compound 48/80 developed beginning at 2–4 months old in both sexes (Table 4), and reactivity was sustained at least up to 8 years of age. The number of mast cells and their functions have been reported to gradually mature in the postnatal infant period [14]. Regarding the appropriate body parts for monitoring skin responses, the front of the neck was more susceptible than other parts, such as the abdomen, chest, and backside, in both ID and IV injections (data not shown). Reactivity partly corresponded with mast cell density in body surface areas [11], and the heterogeneity of skin mast cell numbers is based on histological sections of skin [4]. Premonitoring of NR dogs should be done after 4 months of age, at which point the reactivity would be well developed.

NR dogs have a variety of potential applications. For example, in repeated-dose toxicology studies, researchers sometimes encounter skin reactions that are not distinguished by either immune-mediated allergic reactions or anaphylactoid skin responses. If the reaction disappeared when applied to NR dogs, the mechanism would be determined to be an anaphylactoid reaction. Moreover, if an allergic or infective skin disease model in dogs could be established, the pathophysiological functions of the compound 48/80-mediated pathway in mast cells might be clearly illuminated. As the observations here indicated that the dysfunctional pathway in NR dogs was that from the G protein-coupled receptor leading to intracellular Ca²⁺ elevation, mast cells isolated from NR dogs might be useful in studying the mechanism of GPCR-related degranulation.

In summary, this unique phenotype, typified by insensitivity in the compound 48/80-induced degranulation
pathway in mast cells, has been widely retained in beagle dogs by general experimental animal breeders through recessive inheritance. This knowledge concerning this phenotype could lead to better utilization of dogs in studies and aid in model development.

References

1. Adkinson, N.F. Jr., Essayan, D., Gruchalla, R., Haggerty, H., Kawabata, T., Sandler, J.D., Updyke, L., Shear, N.H., Wierda, D., Health and Environmental Sciences Institute Task Force 2002. Task force report: future research needs for the prevention and management of immune-mediated drug hypersensitivity reactions. *J. Allergy Clin. Immunol.* 109: S461–S478. [Medline] [CrossRef]

2. Endo, K. and Yamasaki, H. 1969. Dogs refractory to compound 48/80 and sinomenine. *Acta Med. Okayama* 23: 589–592. [Medline]

3. Ferry, X., Brehin, S., Kamel, R., and Landry, Y. 2002. G protein-dependent activation of mast cell by peptides and basic secretagogues. *Peptides* 23: 1507–1515. [Medline] [CrossRef]

4. Hill, M. 1998. A review of mast cell biology. *Vet. Dermatol.* 9: 145–166. [CrossRef]

5. Hisatomi, A., Kimura, M., Maeda, M., Matsumoto, M., Ohara, K., and Noguchi, H. 1993. Toxicity of polyoxyethylene hydrogenated castor oil 60 (HCO-60) in experimental animals. *J. Toxicol. Sci.* 18(Suppl 3): 1–9. [Medline] [CrossRef]

6. Kurata, M., Kasuga, Y., Nanba, E., Nakamura, H., Asano, T., and Haruta, K. 1995. Flush induced by fluoroquinolones in canine skin. *Inflamm. Res.* 44: 461–465. [Medline] [CrossRef]

7. Masini, E., Planchenault, J., Pezziaardi, F., Gautier, P., and Gagnol, J.P. 1985. Histamine-releasing properties of Polysorbate 80 in vitro and in vivo: correlation with its hypotensive action in the dog. *Agents Actions* 16: 470–477. [Medline] [CrossRef]

8. Mason, I.S. and Lloyd, D.H. 1996. Evaluation of compound 48/80 as a model of immediate hypersensitivity in the skin of dogs. *Vet. Dermatol.* 7: 81–83. [CrossRef]

9. Mori, K., Maru, C., and Takasuna, K. 2000. Characterization of histamine release induced by fluoroquinolone antibacterial agents in-vivo and in-vitro. *J. Pharm. Pharmacol.* 52: 577–584. [Medline] [CrossRef]

10. Mousli, M., Hugli, T.E., Landry, Y., and Bronner, C. 1994. Peptidergic pathway in human skin and rat peritoneal mast cell activation. *Immunopharmacology* 27: 1–11. [Medline] [CrossRef]

11. Selye, H. 1965. The mast cells. Butterworth Inc., Washington.

12. Thong, B.Y. and Tan, T.C. 2011. Epidemiology and risk factors for drug allergy. *Br. J. Clin. Pharmacol.* 71: 684–700. [Medline] [CrossRef]

13. Vogelnest, L.J. and Mueller, R.S. 2001. The use of compound 48/80 and codeine phosphate as positive controls for intradermal skin testing in dogs. *Vet. Dermatol.* 12: 93–99. [Medline] [CrossRef]

14. Wilkes, L.K., McMenamin, C., and Holt, P.G. 1992. Postnatal maturation of mast cell subpopulations in the rat respiratory tract. *Immunology* 75: 535–541. [Medline]